BOCI maintained a Buy rating for PHARMARON due to strong revenue growth, an increase in new orders, and robust demand for small-molecule CDMO services. The firm raised its revenue forecasts for 2026 and 2027, reflecting faster project conversion. Although the company trades at a discount compared to high-growth peers, its improving profitability and rising CDMO contribution support the positive outlook.
